Lenvatinib and pembrolizumab with transarterial
chemoembolisation for treating hepatocellular
carcinoma

Lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) is being developed
as a first-line treatment for incurable/non-metastatic hepatocellular carcinoma (HCC). HCC is the
most common type of liver cancer. This type of cancer develops from the main form of liver cells,
called hepatocytes. Treatment and survival depends on the stage at which the cancer is
diagnosed, non-metastatic means the cancer has not spread from the liver to other parts of the
body. HCC is more common in people who have long‐term damage to the liver (cirrhosis) due to
hepatitis B or C or excessive alcohol intake and metabolic causes such as obesity. It is also more
likely to develop in men than in women and it becomes more common as people get older.